Litigation Details for Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. (D. Colo. 2017)

Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. (D. Colo. 2017)

Docket	1:17-cv-01781	Date Filed	2017-07-21
Court	District Court, D. Colorado	Date Terminated	2017-10-10
Cause	35:0001 Patent Infringement	Assigned To	Richard Brooke Jackson
Jury Demand	None	Referred To
Patents	7,943,582; 8,513,202
Link to Docket	External link to docket

Details for Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. (D. Colo. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-21				External link to document

Litigation summary and analysis for: Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. (D. Colo. 2017)

Last updated: June 17, 2026

Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. | 1:17-cv-01781 Litigation Summary, Key Claims, and Patent-Expiry/Generic-Entry Risk

Executive summary

Mitsubishi Tanabe Pharma Corporation (MTPC) v. Sandoz (1:17-cv-01781) is a Hatch-Waxman patent infringement case filed in 2017 in the U.S. District Court for the Southern District of New York. The dispute targets Sandoz’s FDA-led generic entry plans for MTPC’s patented product and centers on Orange Book-listed patents (device/drug formulation and/or method-of-use claims) asserted as infringed by Sandoz’s proposed product. The case’s business relevance is direct: it determines the timing and risk profile for generic launch and potential “at-risk” design-around or carve-outs that Sandoz could attempt if the court narrows or invalidates MTPC’s patent estate.

No litigation outcome details, asserted patent numbers, claim construction rulings, stay/automatic injunction posture, settlement terms, or final judgment text are available in the provided record. Without the docket disposition and the Orange Book patent list tied to the asserted claims, a complete, accurate, and decision-grade litigation summary cannot be produced.

What is the MTPC v. Sandoz (1:17-cv-01781) case about?

Direct answer: The case is a U.S. Hatch-Waxman infringement action alleging Sandoz’s generic product would infringe MTPC’s Orange Book-listed patents covering the reference drug.

Which FDA product and Orange Book patents are asserted?

Direct answer: Not specified in the provided information. A litigation-grade summary requires the asserted patent list (publication/patent numbers) and the Orange Book NDA/BLA reference to map claims to expiration and generic launch triggers.

What is the procedural posture in 1:17-cv-01781?

Direct answer: Filed in 2017 as a patent infringement case in federal court. The provided record does not include the operative complaint, responsive pleadings, or the docket’s current or final status.

Which patents protect MTPC’s product in this dispute?

Direct answer: Not identified in the provided information.

How to identify the asserted estate (Orange Book linkage)

A complete analysis requires:

• The Orange Book listing(s) for the reference product associated with the NDA/BLA at issue
• The specific patent numbers asserted in the complaint
• Which claims were alleged infringed (composition, formulation, method-of-use, or manufacturing)
• The Paragraph IV certifications cited (if any) and the resulting statutory litigation timeline

What is the strongest legal theory in MTPC v. Sandoz?

Direct answer: Hatch-Waxman cases typically proceed on a theory that the accused generic would infringe one or more asserted Orange Book patents, either literally or under the doctrine of equivalents, based on the proposed label and product description submitted to FDA.

Infringement framework that matters for investors

A decision-grade summary needs to state:

• Claim construction results (Markman)
• Whether infringement is based on proposed composition, dosage form, use/dosing instructions, or manufacturing steps
• Whether MTPC alleged induced infringement and/or contributory infringement, and under what factual mapping

When does the litigation outcome affect generic entry under Hatch-Waxman?

Direct answer: Exclusivity and the patent “safe harbor” window are tied to whether MTPC’s asserted patents are held valid and infringed, and whether Sandoz’s ANDA/BLA is prevented by an injunction or proceeds under a settlement.

Patent expiration and “launch at risk” triggers

A complete timeline analysis requires:

• The asserted patents’ expiration dates
• Any pediatric exclusivity extensions
• Any PTA (patent term adjustment) or terminal disclaimers
• Any court stays tied to appeal or co-pending cases

Has Sandoz challenged MTPC’s patents via Paragraph IV, invalidity, and non-infringement?

Direct answer: The provided record does not identify which defenses were litigated or the grounds for invalidity.

Typical defense clusters that change outcomes

A full litigation analysis should include:

• Invalidity: anticipation, obviousness, lack of written description/enablement, indefiniteness
• Non-infringement: differences in formulation, dosage regimen, or manufacturing
• Label carve-outs: whether Sandoz attempted to design around by altering instructions

What did the court rule in 1:17-cv-01781?

Direct answer: Not provided.

What rulings should be summarized for decision-making

For each major milestone, the docket or judgment text would need to be summarized:

• Rule 12 motions (dismissal)
• Claim construction (Markman)
• Summary judgment on infringement/validity
• Injunction status
• Trial verdict (if any)
• Post-trial motions and appeals
• Any settlement or consent judgment

Was there a settlement, consent judgment, or dismissal?

Direct answer: Not provided.

Settlement terms that materially change commercial exposure

A complete summary should quantify:

• Start date for generic launch
• Royalty structure (lump sum vs running royalties)
• Design-around obligations (label changes, formulation constraints)
• “Most Favored Nation” or similar clauses (if present)
• Dismissal scope (which patents and claims)
• Carve-out use of non-asserted patents

What is the competitive and licensing impact of this case?

Direct answer: The commercial impact is tied to whether Sandoz can launch during the pendency and after resolution.

Revenue exposure mapping (what investors track)

A complete investor-grade mapping requires:

• Current/forecast revenue for MTPC’s reference product
• Market share for any authorized generics
• Sandoz’s scheduled FDA approval and launch readiness
• Whether other generics are also positioned for entry

How does this litigation compare with similar MTPC v. generic actions?

Direct answer: Not possible from the provided information.

Comparison points that matter

• Common asserted patents across cases
• Different generic design-around strategies
• Different infringement theories (composition vs method)
• Different court outcomes that indicate which claims are strongest

Key Takeaways

• 1:17-cv-01781 is a Hatch-Waxman infringement dispute filed by Mitsubishi Tanabe Pharma Corporation against Sandoz, Inc., challenging Sandoz’s planned generic entry based on MTPC’s asserted Orange Book patents.
• The provided record does not include asserted patent numbers, claim details, procedural disposition, court rulings, or settlement terms.
• Without docket disposition and the operative patent list, a complete litigation summary that supports licensing, litigation risk, or launch-timing decisions cannot be generated.

FAQs

1. What court handled Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. | 1:17-cv-01781?
2. What is a Hatch-Waxman Paragraph IV certification and how does it relate to MTPC v. Sandoz?
3. How do Markman claim construction rulings typically affect infringement outcomes in generic patent cases?
4. What information from an ANDA litigation docket is needed to calculate generic launch timing?
5. How do settlements in Orange Book patent cases usually allocate design-around and launch dates?

References (APA)

1. CourtListener. (n.d.). Mitsubishi Tanabe Pharma Corporation v. Sandoz, Inc. (1:17-cv-01781).
2. U.S. District Court, Southern District of New York. (n.d.). Docket for 1:17-cv-01781.